NCT03070392 2026-03-17
Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma
Immunocore Ltd
Phase 2 Completed
Immunocore Ltd
Pfizer
Iovance Biotherapeutics, Inc.
Bayer
Hoffmann-La Roche
Bristol-Myers Squibb
Merck Sharp & Dohme LLC
Novartis